Drug Trial Radar · NCT00185393
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Last checked: Nov 20, 2026Latest source record: Dec 1, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
414
Actual
Start
Aug 2001
Primary completion
Not stated
Study completion Feb 2007
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to test \[90\]Y-ibritumomab tiuxetan, a radioactive antibody, in patients with stage III or IV follicular lymphoma whose disease is in partial or complete remission after first line chemotherapy. The radioactive antibody will be compared with no further treatment to see which is better in the long term after standard lymphoma treatment.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)Biological
treatment with 90 Yttrium-labeled anti CD 20 antibody
no treatmentOther
no treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: End of study
Locations
95 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Antwerp, Belgium
Site not named
Bruges, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Yvoir, Belgium
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Aarhus, Denmark
Site not named
Copenhagen, Denmark
Site not named
Angers, France
Site not named
Besançon, France
Site not named
Bordeaux, France
Site not named
Créteil, France
Site not named
Grenoble, France
Site not named
Le Mans, France
Site not named
Lille, France
Site not named
Lyon, France
Site not named
Paris, France
Site not named
Pierre-Bénite, France
Site not named
Rouen, France
Site not named
Strasbourg, France
Site not named
Tours, France
Site not named
Rennes, Brittany Region, France
Site not named
Hamburg, Germany
Site not named
Tübingen, Baden-Wurttemberg, Germany
Site not named
Augsburg, Bavaria, Germany
Site not named
München, Bavaria, Germany
Site not named
Göttingen, Lower Saxony, Germany
Site not named
Münster, Nordrhein-Westfalen / 298, Germany
Site not named
Hamm, Nordrhein-Westfalen / 358, Germany
Site not named
Cologne, North Rhine-Westphalia, Germany
Site not named
Düsseldorf, North Rhine-Westphalia, Germany
Site not named
Dresden, Saxony, Germany
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.